Edema
Roche, a global pharmaceutical company, has presented new phase III pivotal data for vamikibart, a non-steroid targeted therapy designed to address inflammation driving uveitic macular edema (UME). The data, presented at the American Academy of Ophthalmology annual meeting (AAO 2025), demonstrate the potential of vamikibart in providing a new treatment
Brolucizumab
Researchers at Southern Medical University in Guangzhou, China, have conducted a study to evaluate the efficacy and safety of intravitreal brolucizumab 6 mg in Chinese subjects with persistent diabetic macular edema. The study, titled "Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST
Diabetic retinopathy
A team of researchers from Queen's University in Belfast, United Kingdom, has presented fresh data on diabetic retinopathy, a leading cause of blindness worldwide. The study, published in the BMJ Open Ophthalmology journal, examined the effects of repeated anti-vascular endothelial growth factor (VEGF) injections on the progression of
Aflibercept
Research from Agostino Gemelli University Hospital in Rome, Italy, has shed light on the effects of a faricimab loading phase on diabetic macular edema. The study, which evaluated 46 eyes with resistant diabetic macular edema, found significant improvements in visual acuity and anatomic outcomes. The findings suggest that faricimab could
Edema
Researchers from Sapienza University of Rome have found that an oral formulation combining bromelain and diosmin has a positive impact on central retinal thickness in patients with diabetic macular edema. This study aimed to assess the effects of this combination on visual acuity and central retinal thickness in patients undergoing
Cleveland Clinic
A new report from researchers at Cleveland Clinic has found that switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy results in significant improvements in diabetic macular edema (DME) patients. The study, published in Ophthalmic Surgery, Lasers and Imaging Retina, analyzed the short-term outcomes of
Bevacizumab
Research conducted by Maharaja Agrasen Medical College has made significant strides in finding an effective and affordable treatment for diabetic macular edema (DME). The study, published in the Indian Journal of Pharmacology, investigated the efficacy and safety of biosimilars of bevacizumab, an off-label anti-vascular endothelial growth factor (VEGF) therapy, in
Edema
A study published in the Journal of Personalized Medicine has shed new light on the effectiveness of faricimab in treating diabetic macular edema (DME). The research, led by investigators at Odense University Hospital, found that faricimab improved best-corrected visual acuity and macular thickness in patients with DME, with treatment intervals
Diabetics
A new system for diabetic macular edema (DME) grading using retinal fundus images has been proposed, offering a timely and accurate diagnosis for this leading cause of vision impairment in diabetic patients. According to research from Instituto Politecnico Nacional, the system integrates multiple deep learning modules to address key aspects
Bromfenac
A recent study by researchers at the Military Medical Academy has found that topical non-steroidal anti-inflammatory drugs, specifically bromfenac, may reduce the treatment burden and improve outcomes for patients with age-related macular degeneration, diabetic macular edema, and retinal vein occlusions. The study, which was published in the journal BMC Ophthalmology,
Edema
A recent study has shed new light on the relationship between reimbursement criteria and treatment patterns among patients with age-related macular degeneration (AMD) and diabetic macular edema (DME). Conducted using Taiwan's National Health Insurance (NHI) database, the research found that changes in reimbursement criteria significantly impacted treatment gaps
Aflibercept
Researchers at F. Hoffmann-La Roche Ltd. have conducted clinical trials to evaluate the efficacy and safety of Faricimab, a novel bispecific antibody targeting VEGF-A and Ang-2, in treating diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The trials, YOSEMITE/RHINE and TENAYA/LUCERNE, compared Faricimab to aflibercept, a
